Pfizer Inc. (PFE)
NYSE · New York, New York, USA · Founded 1849 · CEO Albert Bourla
Valuation summary
$29.34 fair value versus $27.54 in the market, a difference of +6.5%. Rated Hold.
| Fair value per share | $29.34 |
| Current share price | $27.54 |
| Upside / downside | +6.5% |
| Bear case | $17.44 |
| Bull case | $46.04 |
| Discount rate (WACC) | 8.9% |
| Terminal growth | 2.20% |
| Market capitalisation | $157B |
| EV / Sales | 3.5x |
About Pfizer Inc.
Founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn. Albert Bourla has been CEO since 2019 and oversaw the Comirnaty COVID-19 vaccine, which briefly made Pfizer the highest-revenue pharmaceutical company in the world before demand collapsed. The company spent much of that windfall on acquisitions, most significantly $43bn for Seagen in 2023 to build an antibody-drug conjugate oncology franchise. The central question is whether that pipeline can offset a heavy patent cliff.
Investment case
- Seagen gives Pfizer a genuine position in antibody-drug conjugates, one of the most productive areas in oncology.
- The dividend yield is among the highest in large-cap pharma and is covered by current cash flow.
- Expectations are low enough that pipeline surprises are asymmetric to the upside.
Key risks
- A severe patent cliff through the late 2020s affecting Eliquis, Prevnar and several others.
- The COVID revenue collapse was faster and deeper than management guided, which damaged credibility.
- Heavy debt load taken on to fund Seagen limits further business development.
Recent developments
- 2026-08-04 · Q2 revenue $15.03bn, up 3%, and adjusted EPS $0.77 beat estimates; GAAP loss on $4.3bn impairments; 2026 revenue guidance raised to $60.5–62.5bn. source
Revenue by segment
| Oncology | 27% |
| Primary Care | 26% |
| Specialty Care | 24% |
| Hospital & Other | 23% |
Five-year forecast
| Revenue | Free cash flow | |
|---|---|---|
| Year 1 | $63.9B | $16.4B |
| Year 2 | $64.9B | $16.2B |
| Year 3 | $65.9B | $16.1B |
| Year 4 | $67.1B | $15.9B |
| Year 5 | $68.5B | $15.8B |
What the street says
One of the more divided large-cap pharma names. Second-quarter 2026 results beat expectations, the revenue range was raised to $60.5–62.5bn and the CEO bought about $1m of stock in August; bears still point to the patent cliff, including Eliquis exclusivity loss around 2028, and a mixed acquisition record.
Comparable companies: GSK · ZTS · DHR · NVO · BMY · NVS · GILD · TAK
Open the interactive model, price chart and sensitivity grid →